Executive interview – Paion

Published on 10 December 2018

CEO Dr Wolfgang Söhngen provides an overview of Paion’s core technology, Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic. He also discusses the group’s strategy including partnership deals with Cosmo and Mundipharma and the path to market for Paion’s products.

Share this with friends and colleagues